Latest Results From an Ongoing First-in-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Zulfa Omer et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 5
777 Initial clinical characterization of novel proximal biomarkers for NX-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced malignanciesSarah Whelan, Janine Powers, Christopher Karim et al.|Regular and Young Investigator Award Abstracts|2022Cited by 2
CLL-638 Latest Results From an Ongoing Firstin-Human Phase 1a/B Study of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, in Patients With Relapsed/Refractory CLL and Other B-Cell MalignanciesKim Linton, Alexey V. Danilov, Graham P. Collins et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 2